These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 24560758)
1. Does family history of prostate cancer affect outcomes following radiotherapy? Bagshaw H; Ruth K; Horwitz EM; Chen DY; Buyyounouski MK Radiother Oncol; 2014 Feb; 110(2):229-34. PubMed ID: 24560758 [TBL] [Abstract][Full Text] [Related]
2. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970 [TBL] [Abstract][Full Text] [Related]
3. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Foster B; Jackson W; Foster C; Dess R; Abu-Isa E; McLaughlin PW; Merrick G; Hearn J; Spratt D; Liauw S; Hamstra D Am J Clin Oncol; 2019 Apr; 42(4):382-390. PubMed ID: 30724780 [TBL] [Abstract][Full Text] [Related]
4. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766 [TBL] [Abstract][Full Text] [Related]
5. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452 [TBL] [Abstract][Full Text] [Related]
6. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793 [TBL] [Abstract][Full Text] [Related]
7. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325 [TBL] [Abstract][Full Text] [Related]
8. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304 [TBL] [Abstract][Full Text] [Related]
9. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [TBL] [Abstract][Full Text] [Related]
10. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840 [TBL] [Abstract][Full Text] [Related]
11. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132 [TBL] [Abstract][Full Text] [Related]
19. Race as an independent predictor of outcome after treatment for localized prostate cancer. Sohayda CJ; Kupelian PA; Altsman KA; Klein EA J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191 [TBL] [Abstract][Full Text] [Related]
20. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Pollack A; Smith LG; von Eschenbach AC Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]